AVITA Medical to Host Investor Webinar Briefing on Q2 Earnings
PorAinvest
lunes, 11 de agosto de 2025, 4:35 pm ET1 min de lectura
RCEL--
The webinar will cover AVITA Medical's Q2 2025 financial and business results, including its revenue growth and adjusted financial guidance. The company reported a 21.2% increase in total revenue to $18.42 million, driven by strong commercial sales. However, the company narrowed its net loss by 35.6% to $9.92 million, reflecting ongoing operational challenges [1].
Despite the revenue growth, AVITA Medical revised its full-year 2025 revenue guidance to a range of $76 million to $81 million, a 19% to 27% increase over 2024. This reduction was attributed to a 20% decline in RECELL demand during the first half of 2025 due to the reimbursement backlog [1].
The webinar will also discuss the company's strategic direction and product portfolio, which includes the FDA-approved RECELL System and Spray-On Skin Cells. The RECELL System harnesses the healing properties of a patient's own skin to create Spray-On Skin Cells, offering an innovative solution for improved clinical outcomes at the point-of-care [2].
Investors are encouraged to attend the webinar and submit their questions through the registration page. A replay will be available on AVITA Medical's investor relations website following the presentation [2].
References:
[1] https://www.ainvest.com/news/avita-medical-2025-q2-earnings-narrowed-losses-revenues-guidance-cut-2508/
[2] https://www.stocktitan.net/news/RCEL/avita-medical-to-host-investor-webinar-hhsoimnv4o5b.html
AVITA Medical will host an investor webinar on August 14, 2025, to discuss its second-quarter financial results. CEO Jim Corbett and CFO David O'Toole will present and answer questions. The webinar will be available for replay on the company's investor relations website. AVITA Medical specializes in acute wound care and has FDA-approved products like the RECELL System and Spray-On Skin Cells.
AVITA Medical (NASDAQ: RCEL), a leading therapeutic acute wound care company, will host an investor webinar on August 14, 2025, to discuss its second-quarter financial results. The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will provide insights into the company's performance and answer questions from investors [2].The webinar will cover AVITA Medical's Q2 2025 financial and business results, including its revenue growth and adjusted financial guidance. The company reported a 21.2% increase in total revenue to $18.42 million, driven by strong commercial sales. However, the company narrowed its net loss by 35.6% to $9.92 million, reflecting ongoing operational challenges [1].
Despite the revenue growth, AVITA Medical revised its full-year 2025 revenue guidance to a range of $76 million to $81 million, a 19% to 27% increase over 2024. This reduction was attributed to a 20% decline in RECELL demand during the first half of 2025 due to the reimbursement backlog [1].
The webinar will also discuss the company's strategic direction and product portfolio, which includes the FDA-approved RECELL System and Spray-On Skin Cells. The RECELL System harnesses the healing properties of a patient's own skin to create Spray-On Skin Cells, offering an innovative solution for improved clinical outcomes at the point-of-care [2].
Investors are encouraged to attend the webinar and submit their questions through the registration page. A replay will be available on AVITA Medical's investor relations website following the presentation [2].
References:
[1] https://www.ainvest.com/news/avita-medical-2025-q2-earnings-narrowed-losses-revenues-guidance-cut-2508/
[2] https://www.stocktitan.net/news/RCEL/avita-medical-to-host-investor-webinar-hhsoimnv4o5b.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios